{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:47:43Z","timestamp":1793371663520,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg Cases"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but potentially fatal immune-related adverse event (irAE) that may interrupt planned curative treatment for resectable non-small-cell lung cancer. However, the suitability of definitive surgery after recovery from fulminant myocarditis remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 53-year-old man with left upper lobe adenocarcinoma and ipsilateral hilar nodal disease was administered four cycles of neoadjuvant cisplatin, pemetrexed, and pembrolizumab, resulting in a partial response. Eighty-six days after the initiation of neoadjuvant chemoimmunotherapy, he developed grade 4 fulminant ICI-associated myocarditis with ventricular fibrillation and cardiac arrest. Endomyocardial biopsy revealed active lymphocytic myocarditis. The patient required intubation, percutaneous cardiopulmonary support, intra-aortic balloon pumping, continuous hemodiafiltration, high-dose corticosteroids, and prolonged rehabilitation. After his cardiac function recovered, tumor regrowth without distant metastasis was identified. Multidisciplinary reassessment supported surgery because the left ventricular ejection fraction had recovered to 71%, no recurrent malignant arrhythmia had been documented, cardiac biomarkers had improved, prednisolone had been tapered to 10\u00a0mg\/day, and the disease remained technically resectable. Thoracoscopic-assisted thoracotomy with left upper lobe sleeve resection, pulmonary artery reconstruction, and hilar and mediastinal lymph node dissection was performed 144\u00a0days after myocarditis onset, corresponding to 230\u00a0days after the initiation of neoadjuvant chemoimmunotherapy. R0 resection was achieved. Surveillance computed tomography showed no evidence of recurrence through 3.5\u00a0years after surgery, and the patient was alive at the last follow-up 6.3\u00a0years after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fulminant ICI-associated myocarditis does not necessarily preclude subsequent curative-intent lung resection. In highly selected patients, surgery may remain feasible after objective cardiac recovery, multidisciplinary reassessment, and shared decision-making with the patient. This case suggests that the acute management of life-threatening cardiovascular irAEs should be undertaken at centers with continuous on-site cardiology support, multidisciplinary care, and access to emergency mechanical circulatory support. Additionally, planning subsequent curative-intent surgery requires multidisciplinary collaboration, ready access to cardiology expertise, and an appropriate pathway for rapid escalation of cardiovascular care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s44215-026-00278-x","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:52:23Z","timestamp":1791543143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Curative-intent lung resection after recovery from fulminant immune checkpoint inhibitor-associated myocarditis during neoadjuvant therapy: a case report"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7770-4141","authenticated-orcid":false,"given":"Yui","family":"Kaburaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsunematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikki","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389:491\u2013503.","journal-title":"N Engl J Med"},{"key":"278_CR2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"278_CR4","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"278_CR5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141:2031\u20134.","journal-title":"Circulation"},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1390\u20139.","journal-title":"JAMA Oncol"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, Gradone A, Azam TU, Perry D, et al. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOncol. 2022;4:689\u2013700.","journal-title":"JACC CardioOncol"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"e01177","DOI":"10.1213\/XAA.0000000000001177","volume":"14","author":"RT Nierstedt","year":"2020","unstructured":"Nierstedt RT, Yeahia R, Barnett KM. Unanticipated myocarditis in a surgical patient treated with pembrolizumab: a case report. A A Pract. 2020;14:e01177.","journal-title":"A A Pract"},{"key":"278_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2025.02.004","volume":"7","author":"G Bailly","year":"2025","unstructured":"Bailly G, Robert-Halabi M, Vion PA, Allenbach Y, Abbar B, Bretagne M, et al. Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown. JACC CardioOncol. 2025;7:300\u20134.","journal-title":"JACC CardioOncol"},{"key":"278_CR10","first-page":"100930","volume":"7","author":"T Watanabe","year":"2026","unstructured":"Watanabe T, Nomura K, Takamori S, Tane S, Ohara S, Oiki H, et al. Preoperative immune-related adverse events in resectable NSCLC treated with neoadjuvant nivolumab plus chemotherapy: a multicenter retrospective analysis. JTO Clin Res Rep. 2026;7:100930.","journal-title":"JTO Clin Res Rep"}],"container-title":["General Thoracic and Cardiovascular Surgery Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-026-00278-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44215-026-00278-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-026-00278-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:02:15Z","timestamp":1791586935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44215-026-00278-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1186\/s44215-026-00278-x","relation":{},"ISSN":["2731-6203"],"issn-type":[{"value":"2731-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the policy of the Institutional Review Board of Kanagawa Cancer Center, formal IRB approval was not required for this case report.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.I. received honoraria from MSD. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"45"}}